Header Logo

Connection

MICHAEL E RYTTING to Adult

Back to Details
This is a "connection" page, showing publications MICHAEL E RYTTING has written about Adult.
MICHAEL E RYTTING
Connection Strength
0.242
Adult
  1. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403.
    View in: PubMed
    Score: 0.022
  2. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
    View in: PubMed
    Score: 0.021
  3. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
    View in: PubMed
    Score: 0.018
  4. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014 Feb; 61(2):369-72.
    View in: PubMed
    Score: 0.017
  5. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 2013 Sep; 88(9):784-9.
    View in: PubMed
    Score: 0.017
  6. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8.
    View in: PubMed
    Score: 0.014
  7. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010 May; 10(5):833-9.
    View in: PubMed
    Score: 0.014
  8. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e991-e996.
    View in: PubMed
    Score: 0.008
  9. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 11; 35(11):3282-3286.
    View in: PubMed
    Score: 0.007
  10. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021 03; 68(3):e28888.
    View in: PubMed
    Score: 0.007
  11. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218.
    View in: PubMed
    Score: 0.007
  12. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
    View in: PubMed
    Score: 0.006
  13. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66.
    View in: PubMed
    Score: 0.005
  14. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9.
    View in: PubMed
    Score: 0.005
  15. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
    View in: PubMed
    Score: 0.005
  16. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol. 2015 May; 123(1):85-91.
    View in: PubMed
    Score: 0.005
  17. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
    View in: PubMed
    Score: 0.005
  18. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61.
    View in: PubMed
    Score: 0.005
  19. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6.
    View in: PubMed
    Score: 0.005
  20. The association between opioid administration and response to therapy in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1903-5.
    View in: PubMed
    Score: 0.005
  21. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65.
    View in: PubMed
    Score: 0.005
  22. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
    View in: PubMed
    Score: 0.004
  23. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
    View in: PubMed
    Score: 0.004
  24. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
    View in: PubMed
    Score: 0.004
  25. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 01; 118(3):848-55.
    View in: PubMed
    Score: 0.004
  26. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9.
    View in: PubMed
    Score: 0.004
  27. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):875-90.
    View in: PubMed
    Score: 0.003
  28. Unusual expression of CD94 on CD8+ TCR-alpha beta T cells in infectious mononucleosis. Ann Diagn Pathol. 2007 Feb; 11(1):55-60.
    View in: PubMed
    Score: 0.003
  29. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
    View in: PubMed
    Score: 0.003
  30. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006 Jun 01; 106(11):2495-502.
    View in: PubMed
    Score: 0.003
  31. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20; 24(12):1917-23.
    View in: PubMed
    Score: 0.003
  32. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22.
    View in: PubMed
    Score: 0.002
  33. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
    View in: PubMed
    Score: 0.002
  34. Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anticancer Drugs. 1999 Jul; 10(6):519-24.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.